Evaluation of prognostic factors in radical prostatectomy specimens with cancer

Prostate cancer (PCa) is a leading cause of morbidity and mortality in males accounting for approximately 30% of all new cases of cancer and approximately 14% of cancer deaths. Despite considerable advances achieved in the ability to detect and treat PCa, there have not been significant corresponding decreases in PCa-related morbidity and mortality. Proper examination of radical prostatectomy specimens by the pathologists is critical in determining the need for adjuvant treatment and prediction of patient outcome. The goal is to tailor the therapeutic approach to the clinical, morphological and molecular features of each patient.